Business Wire

Velodyne Lidar Calls for Action to Improve Pedestrian Safety

20.10.2020 15:00:00 EEST | Business Wire | Press release

Share

Velodyne Lidar, Inc. (Nasdaq: VLDR) today published a white paper that calls for independent performance testing of driver assistance systems to be expanded to include dark nighttime scenarios. The change would address a gap in current testing protocols that primarily looks at daytime conditions and largely overlooks the risks to pedestrians from driver assistance systems that perform poorly in dark nighttime conditions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020005335/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Side by side comparison of images produced by automotive camera and Velodyne’s Velarray lidar in dark conditions with streetlights and low beam headlights. (Graphic: Velodyne Lidar, Inc.)

The white paper, called “Improving Pedestrian Automatic Emergency Braking (PAEB) in Dark, Nighttime Conditions,” can be downloaded here.

Over 6,000 pedestrians are killed every year in traffic-related crashes in the United States with the vast majority of fatalities occurring in dark conditions. To address these tragedies, most new vehicles offer advanced driver assistance systems (ADAS) equipped with Pedestrian Automatic Emergency Braking (PAEB) as a standard or optional feature.

PAEB systems provide automatic braking for vehicles when pedestrians are in the path of the vehicle’s travel and the driver has taken insufficient action to avoid an imminent crash. However, current systems utilizing camera and radar technology frequently fail to protect pedestrians in dark conditions according to independent testing by the National Highway Traffic Safety Association (NHTSA) and the American Automobile Association (AAA).

To reflect real-life conditions, the white paper proposes expanding future PAEB testing protocols to include tests conducted in dark, nighttime conditions. The new tests would be conducted in less than one lux ambient illuminance, using low-beam headlights and without streetlights. This change would provide the public with useful information on the performance of pedestrian detection systems in low-light conditions that occur on roadways.

To demonstrate how expanded testing would work, the white paper details the results of nighttime PAEB tests conducted by Velodyne. The tests evaluated a highly-rated PAEB system using current camera and radar-based technology and Velodyne’s PAEB system that uses Velodyne’s lidar sensors and Vella™ software. In these nighttime conditions, the camera and radar-based PAEB system failed in all five scenarios while the lidar-based system avoided a crash in every situation tested.

“With dark nighttime conditions so dangerous for pedestrians, it is imperative vehicle assessment organizations expand PAEB testing in ambient light conditions of less than one lux,” said David Heeren, Sr. Technical Product Marketing Manager, Velodyne Lidar. “Tests performed by NHTSA and AAA demonstrate nighttime performance represents a major opportunity for improvement in current PAEB systems. Velodyne testing shows the efficacy of our lidar-based solution, which can strengthen a vehicle’s functional safety capabilities and address scenarios that cause thousands of pedestrian fatalities annually.”

About Velodyne Lidar

Velodyne Lidar (NASDAQ: VLDR) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Landis Communications Inc.
Sean Dowdall
(415) 286-7121
velodyne@landispr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 12:00:00 EEST | Press release

WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, uses biomarker data, including temperature and heart rate data, to identify fertile and non-fertile days, helping users prevent pregnancy without hormones while also providing fertility insights. Beyond birth control, the app

Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 11:00:00 EEST | Press release

Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphatax's long-term vision for the future of tax technology. By bringing these transfer pric

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release

Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye